Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia

Open access
Döhner, Konstanze, Thiede, Christian, Jahn, Nikolaus, Panina, Ekaterina, Gambietz, Agnes, Larson, Richard A., Prior, Thomas W., Marcucci, Guido, Jones, Dan, Krauter, Jürgen, Heuser, Michael, Voso, Maria Teresa, Ottone, Tiziana, Nomdedeu, Josep F., Mandrekar, Sumithra J., Klisovic, Rebecca B., Wei, Andrew H., Sierra, Jorge, Sanz, Miguel A., Brandwein, Joseph M., de Witte, Theo, Jansen, Joop H., Niederwieser, Dietger, Appelbaum, Frederick R., Medeiros, Bruno C., Tallman, Martin S., Schlenk, Richard F., Ganser, Arnold, Serve, Hubert, Ehninger, Gerhard, Amadori, Sergio, Gathmann, Insa, Benner, Axel, Pallaud, Celine, Stone, Richard M., Döhner, Hartmut, Bloomfield, Clara D. · 2020 · Blood

Abstract

Patients with acute myeloid leukemia (AML) harboring FLT3 internal tandem duplications (ITDs) have poor outcomes, in particular AML with a high (≥0.5) mutant/wild-type allelic ratio (AR). The 2017 European LeukemiaNet (ELN) recommendations defined 4 distinct FLT3-ITD genotypes based on the ITD AR and the NPM1 mutational status. In this retrospective exploratory study, we investigated the prognostic and predictive impact of the NPM1/FLT3-ITD genotypes categorized according to the 2017 ELN risk groups in patients randomized within the RATIFY trial, which evaluated the addition of midostaurin to standard chemotherapy. The 4 NPM1/FLT3-ITD genotypes differed significantly with regard to clinical and concurrent genetic features. Complete ELN risk categorization could be done in 318 of 549 trial patients with FLT3-ITD AML. Significant factors for response after 1 or 2 induction cycles were ELN risk group and white blood cell (WBC) counts; treatment with midostaurin had no influence. Overall survival (OS) differed significantly among ELN risk groups, with estimated 5-year OS probabilities of 0.63, 0.43, and 0.33 for favorable-, intermediate-, and adverse-risk groups, respectively (P < .001). A multivariate Cox model for OS using allogeneic hematopoietic cell transplantation (HCT) in first complete remission as a time-dependent variable revealed treatment with midostaurin, allogeneic HCT, ELN favorable-risk group, and lower WBC counts as significant favorable factors. In this model, there was a consistent beneficial effect of midostaurin across ELN risk groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019002697

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 197

Metadata

Authors
Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R. A., Prior, T. W., Marcucci, G., Jones, D., Krauter, J., Heuser, M., Voso, M. T., Ottone, T., Nomdedeu, J. F., Mandrekar, S. J., Klisovic, R. B., Wei, A. H., Sierra, J., Sanz, M. A., Brandwein, J. M., de Witte, T., Jansen, J. H., Niederwieser, D., Appelbaum, F. R., Medeiros, B. C., Tallman, M. S., Schlenk, R. F., Ganser, A., Serve, H., Ehninger, G., Amadori, S., Gathmann, I., Benner, A., Pallaud, C., Stone, R. M., Döhner, H., & Bloomfield, C. D.
Venue
Blood
Published
2020-01-30
Volume
135
Issue
5
Pages
371-380
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2994880414
Cited by
197
References
3
FWCI
12.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood.2019002697
The paper
Döhner, K., Thiede, C., Jahn, N., Panina, E., Gambietz, A., Larson, R. A., Prior, T. W., Marcucci, G., Jones, D., Krauter, J., Heuser, M., Voso, M. T., Ottone, T., Nomdedeu, J. F., Mandrekar, S. J., Klisovic, R. B., Wei, A. H., Sierra, J., Sanz, M. A., . . . Bloomfield, C. D. (2020). Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. https://doi.org/10.1182/blood.2019002697

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.